2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to
... incorporated where appropriate, but there were no substantive changes as the bulk of the content was undisputed. ...
... incorporated where appropriate, but there were no substantive changes as the bulk of the content was undisputed. ...
Guidelines for Monitoring and Management of Pediatric Patients
... (eg, fracture reduction), either single agents with analgesic/ sedative properties or combination regimens are commonly used. Anxiolysis and amnesia are additional goals that should be considered in selection of agents for particular patients. However, the potential for an adverse outcome may be inc ...
... (eg, fracture reduction), either single agents with analgesic/ sedative properties or combination regimens are commonly used. Anxiolysis and amnesia are additional goals that should be considered in selection of agents for particular patients. However, the potential for an adverse outcome may be inc ...
Drug utilisation sub-committee (DUSC)
... note that meta-analyses have not shown superior efficacy compared to other benzodiazepines, but have shown a greater risk of dependence, problematic use and withdrawal.5, 6 In addition to panic disorder, alprazolam is registered for short term symptomatic treatment of anxiety. The current Therapeuti ...
... note that meta-analyses have not shown superior efficacy compared to other benzodiazepines, but have shown a greater risk of dependence, problematic use and withdrawal.5, 6 In addition to panic disorder, alprazolam is registered for short term symptomatic treatment of anxiety. The current Therapeuti ...
Amiodarone Inhibits the Na -K Pump in Rabbit Cardiac Myocytes
... quantities of amiodarone were made up at two weekly intervals. A single daily amiodarone capsule was administered to rabbits orally in a dose of 80 mg/kg/day for 4 weeks. This protocol was based on a previous study in rabbits demonstrating clinically relevant changes in electrophysiological and elec ...
... quantities of amiodarone were made up at two weekly intervals. A single daily amiodarone capsule was administered to rabbits orally in a dose of 80 mg/kg/day for 4 weeks. This protocol was based on a previous study in rabbits demonstrating clinically relevant changes in electrophysiological and elec ...
Lipid Modification (update): draft NICE guideline
... most patients would choose the intervention. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the strength of the recommendation). For all recommendations, NICE expects that there is discussion with the patient about the risks and ...
... most patients would choose the intervention. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the strength of the recommendation). For all recommendations, NICE expects that there is discussion with the patient about the risks and ...
Misoprostol Use in Obstetrics and Gynecology
... Both vaginal and oral administration appear effective for treatment of incomplete abortion.15 With either route, multiple doses may be required. Vaginal administration generally allows more time between doses16 and appears more effective for cervical ripening and induction of abortion than oral admi ...
... Both vaginal and oral administration appear effective for treatment of incomplete abortion.15 With either route, multiple doses may be required. Vaginal administration generally allows more time between doses16 and appears more effective for cervical ripening and induction of abortion than oral admi ...
capsaicin - PAN Pesticide Database
... the cecum were induced in 22% of females and 14% of males, whereas the corresponding tumor incidences in untreated female and male controls were both 8%. Histopathologically, the tumors were classified as benign polypoid adenomas. [Toth B, Gannett P; In Vivo 6 (1): 59-63 (1992)]**PEER REVIEWED** Pre ...
... the cecum were induced in 22% of females and 14% of males, whereas the corresponding tumor incidences in untreated female and male controls were both 8%. Histopathologically, the tumors were classified as benign polypoid adenomas. [Toth B, Gannett P; In Vivo 6 (1): 59-63 (1992)]**PEER REVIEWED** Pre ...
SUMMARY OF DATA FOR CHEMICAL SELECTION BASIS OF NOMINATION
... The FDA considers Herbal Ecstasy to be a street drug alternative, not a dietary supplement. Since street drug alternatives have a potential for abuse, FDA considers them to be unapproved new drugs and misbranded drugs under sections 505 and 502of the Federal Food, Drug, and Cosmetic Act (FDA, 2000; ...
... The FDA considers Herbal Ecstasy to be a street drug alternative, not a dietary supplement. Since street drug alternatives have a potential for abuse, FDA considers them to be unapproved new drugs and misbranded drugs under sections 505 and 502of the Federal Food, Drug, and Cosmetic Act (FDA, 2000; ...
HIV/AIDS Guidelines
... Table 14. Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonist .........K-17 Table 15a. Drug Interactions between PIs and Other Drugs .............................................K-19 Table 15b. Drug Interactions between NNRTIs and Other Drugs......................................K-30 ...
... Table 14. Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonist .........K-17 Table 15a. Drug Interactions between PIs and Other Drugs .............................................K-19 Table 15b. Drug Interactions between NNRTIs and Other Drugs......................................K-30 ...
Pfizer Guitly of Violating California Unfair Competition Law
... Quantifying the Fraud. . . . . . 138 ...
... Quantifying the Fraud. . . . . . 138 ...
cocaine-induced behavioral sensitization and
... Americans met criteria for abuse or dependence of cocaine in accordance with the Diagnostic and Statistical Manual of Mental Disorders. After decades of research, no FDA-approved medications are available to treat cocaine addiction. The current treatment regime, therefore, is restricted to behavior ...
... Americans met criteria for abuse or dependence of cocaine in accordance with the Diagnostic and Statistical Manual of Mental Disorders. After decades of research, no FDA-approved medications are available to treat cocaine addiction. The current treatment regime, therefore, is restricted to behavior ...
Methadone-Drug Interactions
... inhibition is involved. Overmedication reactions are likely due to CYP inhibition that develops quickly; within a few days after concurrent drug administration. In contrast, CYP induction is slower to emerge, commonly taking about a week to produce significant withdrawal signs/symptoms (Antoniou and ...
... inhibition is involved. Overmedication reactions are likely due to CYP inhibition that develops quickly; within a few days after concurrent drug administration. In contrast, CYP induction is slower to emerge, commonly taking about a week to produce significant withdrawal signs/symptoms (Antoniou and ...
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid
... A. Genetic factors predicting increased risk of drug toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 B. Genetic factors predicting increased drug efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 Acknowledgments. . . . . . . . . . ...
... A. Genetic factors predicting increased risk of drug toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 B. Genetic factors predicting increased drug efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 Acknowledgments. . . . . . . . . . ...
Tumescent Technique Chronicles Local Anesthesia, Liposuction
... convinced me that liposuction was destined to become an important dermatologic surgical procedure. In February 1985, I attended a liposuction course given by Gary Fenno, MD and sponsored by the American Society for Liposuction Surgery. None of the faculty had done liposuction by local anesthesia. L ...
... convinced me that liposuction was destined to become an important dermatologic surgical procedure. In February 1985, I attended a liposuction course given by Gary Fenno, MD and sponsored by the American Society for Liposuction Surgery. None of the faculty had done liposuction by local anesthesia. L ...
the selection and use of essential medicines
... Dr H.V. Hogerzeil, Director of the Department of Medicines Policy and Standards, and Secretary of the Expert Committee, also welcomed the participants. He noted that this would be the third Expert Committee operating under the new procedures approved in 2002. The full effect of these new procedures ...
... Dr H.V. Hogerzeil, Director of the Department of Medicines Policy and Standards, and Secretary of the Expert Committee, also welcomed the participants. He noted that this would be the third Expert Committee operating under the new procedures approved in 2002. The full effect of these new procedures ...
67Dihydroxybergamottin Contributes to the Grapefruit
... Objective: Our objective was to assess the contribution of 6',7'-dihydroxybergamottin (DHB) to the inhibitory effect of grapefruit juice toward intestinal cytochrome P450 (CYP) 3A4. Methods: An aqueous extract was prepared from grapefruit juice by centrifugation, filtration, and repeated washing of ...
... Objective: Our objective was to assess the contribution of 6',7'-dihydroxybergamottin (DHB) to the inhibitory effect of grapefruit juice toward intestinal cytochrome P450 (CYP) 3A4. Methods: An aqueous extract was prepared from grapefruit juice by centrifugation, filtration, and repeated washing of ...
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage
... not receiving concomitant myelosuppressive chemotherapy. Pts with myeloid cancer. For all uses: 1) Pretreatment (no erythropoietin treatment in previous month) Hgb is less than 10 g/dL, 2) For reauthorizations (patient received erythropoietin in previous month), an increase in Hgb of at least 1 g/dL ...
... not receiving concomitant myelosuppressive chemotherapy. Pts with myeloid cancer. For all uses: 1) Pretreatment (no erythropoietin treatment in previous month) Hgb is less than 10 g/dL, 2) For reauthorizations (patient received erythropoietin in previous month), an increase in Hgb of at least 1 g/dL ...
Syllabus of Eclectic Materia Medica and Therapeutics
... symptom or expression is the effect, like symptoms must show like conditions. "It may be urged that the symptoms of disease are some times masked, ox: that the evidence of grave disease may be covered up by symptoms of minor wrongs (usually of the nervous system), or that patients and nurses may mis ...
... symptom or expression is the effect, like symptoms must show like conditions. "It may be urged that the symptoms of disease are some times masked, ox: that the evidence of grave disease may be covered up by symptoms of minor wrongs (usually of the nervous system), or that patients and nurses may mis ...
attenuating trigeminal neuropathic pain by
... dose attenuated facial pain. The third experiment determined that combining ineffective low doses of PIO and D-cycloserine (DCS) produced a potentiated anti-allodynic response of these drugs and attenuated the anxiety associated with the TIC injury. Ex vivo studies revealed that cortical mitochondri ...
... dose attenuated facial pain. The third experiment determined that combining ineffective low doses of PIO and D-cycloserine (DCS) produced a potentiated anti-allodynic response of these drugs and attenuated the anxiety associated with the TIC injury. Ex vivo studies revealed that cortical mitochondri ...
Berberine Monograph - Alternative Medicine Review
... Copyright©2000 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission ...
... Copyright©2000 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission ...
Differential Reinforcement of Low Rate Performance
... obtained from the same laboratory with the use of different behavioral measures or paradigms (De Angelis et al., 1982; Ghoneim et al., 1986; Loke et al., 1985). Our study is an expansion of the previous work on both behavior and PK, which aims to validate the interaction of alprazolam and caffeine b ...
... obtained from the same laboratory with the use of different behavioral measures or paradigms (De Angelis et al., 1982; Ghoneim et al., 1986; Loke et al., 1985). Our study is an expansion of the previous work on both behavior and PK, which aims to validate the interaction of alprazolam and caffeine b ...
$doc.title
... methylphenidate have no evidence of movement disorders or tics due to the medication. Second, there is minimal concern for methylphenidate-induced growth restriction. This conclusion is based on growth restriction being observed in animal studies only at high doses of methylphenidate using a non-the ...
... methylphenidate have no evidence of movement disorders or tics due to the medication. Second, there is minimal concern for methylphenidate-induced growth restriction. This conclusion is based on growth restriction being observed in animal studies only at high doses of methylphenidate using a non-the ...
Guideline on Steroids in Pregnancy
... mg/kg at 7 day intervals, starting from 3 weeks before delivery, the birth weight of foetal lambs was found to be reduced (by 15% after one dose, 19% after two doses, and 27% after three and four doses) [22]. It is noteworthy that considerable amounts of betamethasone 17, 21-dipropionate appeared in ...
... mg/kg at 7 day intervals, starting from 3 weeks before delivery, the birth weight of foetal lambs was found to be reduced (by 15% after one dose, 19% after two doses, and 27% after three and four doses) [22]. It is noteworthy that considerable amounts of betamethasone 17, 21-dipropionate appeared in ...
Over-the-Counter Medications
... or toxic in children. Examples of prescription FDA’s Decision Tree for Determining Whether Pediatric Efficacy Studies of a Drug Are Needed. drugs include sumatripModified from FDA presentation, “Guidance for Industry: Exposure–Response Relationships — tan, gabapentin, and Study Design, Data Analysis ...
... or toxic in children. Examples of prescription FDA’s Decision Tree for Determining Whether Pediatric Efficacy Studies of a Drug Are Needed. drugs include sumatripModified from FDA presentation, “Guidance for Industry: Exposure–Response Relationships — tan, gabapentin, and Study Design, Data Analysis ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.